Learn more

STRONGBRIDGE DUBLIN LTD

Overview
  • Total Patents
    29
  • GoodIP Patent Rank
    54,670
  • Filing trend
    ⇧ 200.0%
About

STRONGBRIDGE DUBLIN LTD has a total of 29 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, measurement and medical technology are TOCHIGI INST OF CLINICAL PATHOLOGY, ARAVAX PTY LTD and SPERMATECH AS.

Patent filings in countries

World map showing STRONGBRIDGE DUBLIN LTDs patent filings in countries
# Country Total Patents
#1 United States 22
#2 WIPO (World Intellectual Property Organization) 6
#3 Australia 1

Patent filings per year

Chart showing STRONGBRIDGE DUBLIN LTDs patent filings per year from 1900 to 2020

Focus industries

# Industry
#1 Pharmaceuticals
#2 Measurement
#3 Medical technology

Top inventors

# Name Total Patents
#1 Cohen Fredric Jay 16
#2 Cohen Fredric 5
#3 Marin Per 2
#4 Koziol Theodore Richard 2
#5 Cohen Fred 1
#6 Afargan Michel 1
#7 Afargan Michael 1
#8 Stewart Timothy Andrew 1

Latest patents

Publication Filing date Title
US2021100760A1 Methods of treating disease with dichlorphenamide
WO2020257037A1 Dichlorphenamide compositions and methods of use
WO2020180784A1 Methods of treating disease with levoketoconazole
US2020170979A1 Methods of treating disease with dichlorphenamide
WO2020074958A1 Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
US2019336567A1 Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
US2020230084A1 Methods of treating disease with dichlorphenamide
US2020230085A1 Methods of treating disease with dichlorphenamide
US2020170972A1 Methods of treating disease with dichlorphenamide
US2020163911A1 Methods of treating disease with dichlorphenamide
AU2017220728A1 Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, SST-R5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors